Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, L.
Right arrow Articles by Jaffe, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, L.
Right arrow Articles by Jaffe, R. B.
[Cancer Research 62, 1087-1092, February 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Inhibition of Phosphatidylinositol 3'-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models1

Limin Hu, Judith Hofmann, Yiling Lu, Gordon B. Mills and Robert B. Jaffe2

Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143-0556 [L. H., J. H., R. B. J.], and Department of Molecular Oncology, M.D. Anderson Cancer Center, Houston, Texas 77030 [Y. L., G. B. M.]

Phosphatidylinositol 3'-kinase (PI3k) is implicated in a wide array of biological and pathophysiological responses. Thus, inhibiting molecules involved in its signal transduction pathway is a possible means of treating cancer. Our previous studies demonstrated that LY294002, a potent and selective PI3k inhibitor, decreases growth of ovarian carcinoma and ascites formation in an athymic mouse xenogeneic transplant model of ovarian cancer. However, the dose of LY294002 used to decrease tumor growth resulted in significant dermatological toxicity. We demonstrate herein that introduction of an active catalytic subunit of PI3k into an ovarian cancer cell line, and thus activation of the PI3k/AKT pathway, confers resistance to the effects of paclitaxel, one of the major drugs used in ovarian cancer therapy. The resistance to paclitaxel can be reversed in vitro by inhibition of PI3k. Therefore, we evaluated whether combined therapy with paclitaxel and LY294002 would result in increased efficacy and allow utilization of doses of LY294002 that do not induce dermatological toxicity. Two weeks after i.p. inoculation with OVCAR-3 ovarian cancer cells, mice were treated i.p. with LY294002 plus paclitaxel, each three times weekly on alternate days, for 4 weeks. Tumor burden in the LY294002 + paclitaxel, LY 294002 alone, and paclitaxel alone groups was reduced by 80% (P < 0.01), 38% (P < 0.05), and 51% (P < 0.05), respectively, compared with controls. Virtually no ascites developed in the combined treatment group; mean volume of ascites in the controls was 3.7 ml. Treatment with LY294002 alone reduced ascites by 70% (P < 0.01), whereas paclitaxel alone reduced ascites slightly but not significantly. No dermatological lesions or weight loss were observed in any treatment group. In vivo and in vitro morphological studies demonstrated that inhibition of PI3k enhanced paclitaxel-induced apoptosis in the human ovarian cancers. Our data suggest that a combination of a PI3k inhibitor and conventional chemotherapy may provide an effective approach to inhibiting tumor growth and ascites production in ovarian cancer with acceptable side effects.




This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
S. J. Peterson, D. H. Kim, M. Li, V. Positano, L. Vanella, L. F. Rodella, F. Piccolomini, N. Puri, A. Gastaldelli, C. Kusmic, et al.
The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice
J. Lipid Res., July 1, 2009; 50(7): 1293 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Blood, May 28, 2009; 113(22): 5549 - 5557.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
V. Unterreiner, Y. Ibig-Rehm, M. Simonen, H. Gubler, and D. Gabriel
Comparison of Variability and Sensitivity between Nuclear Translocation and Luciferase Reporter Gene Assays
J Biomol Screen, January 1, 2009; 14(1): 59 - 65.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al.
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Cancer Res., October 1, 2008; 68(19): 8022 - 8030.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Engels, S. K. Knauer, S. Loibl, V. Fetz, P. Harter, A. Schweitzer, A. Fisseler-Eckhoff, F. Kommoss, L. Hanker, V. Nekljudova, et al.
NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas
Cancer Res., July 1, 2008; 68(13): 5159 - 5166.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C.-X. Xu, D. Jere, H. Jin, S.-H. Chang, Y.-S. Chung, J.-Y. Shin, J.-E. Kim, S.-J. Park, Y.-H. Lee, C.-H. Chae, et al.
Poly(ester amine)-mediated, Aerosol-delivered Akt1 Small Interfering RNA Suppresses Lung Tumorigenesis
Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 60 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S.-M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, et al.
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Mol. Cancer Ther., July 1, 2008; 7(7): 1851 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q.-S. Zhu, W. Ren, B. Korchin, G. Lahat, A. Dicker, Y. Lu, G. Mills, R. E. Pollock, and D. Lev
Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45{alpha}
Cancer Res., April 15, 2008; 68(8): 2895 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. S. Chen, L. J. Zhou, M. Entin-Meer, X. Yang, M. Donker, Z. A. Knight, W. Weiss, K. M. Shokat, D. Haas-Kogan, and D. Stokoe
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Mol. Cancer Ther., April 1, 2008; 7(4): 841 - 850.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Astanehe, D. Arenillas, W. W. Wasserman, P. C. K. Leung, S. E. Dunn, B. R. Davies, G. B. Mills, and N. Auersperg
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer
J. Cell Sci., March 1, 2008; 121(5): 664 - 674.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. N. Landen Jr, M. J. Birrer, and A. K. Sood
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Bakalian, J.-C. Marshall, P. Logan, D. Faingold, S. Maloney, S. Di Cesare, C. Martins, B. F. Fernandes, and M. N. Burnier Jr.
Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma
Clin. Cancer Res., February 15, 2008; 14(4): 951 - 956.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. R. Garlich, P. De, N. Dey, J. D. Su, X. Peng, A. Miller, R. Murali, Y. Lu, G. B. Mills, V. Kundra, et al.
A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
Cancer Res., January 1, 2008; 68(1): 206 - 215.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Furuya, C. Lu, M. C. Willingham, and S.-y. Cheng
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer
Carcinogenesis, December 1, 2007; 28(12): 2451 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Lefranc, V. Facchini, and R. Kiss
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Oncologist, December 1, 2007; 12(12): 1395 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Merighi, A. Benini, P. Mirandola, S. Gessi, K. Varani, E. Leung, S. Maclennan, P. G. Baraldi, and P. A. Borea
Hypoxia Inhibits Paclitaxel-Induced Apoptosis through Adenosine-Mediated Phosphorylation of Bad in Glioblastoma Cells
Mol. Pharmacol., July 1, 2007; 72(1): 162 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin
Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., May 15, 2007; 13(10): 3015 - 3023.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C.-Y. Jin, D.-O. Moon, J.-D. Lee, M.-S. Heo, Y. H. Choi, C.-M. Lee, Y.-M. Park, and G.-Y. Kim
Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells
Carcinogenesis, May 1, 2007; 28(5): 1058 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. Vandermoere, I. E. Yazidi-Belkoura, Y. Demont, C. Slomianny, J. Antol, J. Lemoine, and H. Hondermarck
Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt
Mol. Cell. Proteomics, January 1, 2007; 6(1): 114 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. E. Cristiano, J. C. Chan, K. M. Hannan, N. A. Lundie, N. J. Marmy-Conus, I. G. Campbell, W. A. Phillips, M. Robbie, R. D. Hannan, and R. B. Pearson
A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition
Cancer Res., December 15, 2006; 66(24): 11718 - 11725.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Sain, B. Krishnan, M. G. Ormerod, A. De Rienzo, W. M. Liu, S. B. Kaye, P. Workman, and A. L. Jackman
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
Mol. Cancer Ther., May 1, 2006; 5(5): 1197 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al.
Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models
Endocrinology, April 1, 2006; 147(4): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris
Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice.
Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Davidson, V. Espina, S. M. Steinberg, V. A. Florenes, L. A. Liotta, G. B. Kristensen, C. G. Trope, A. Berner, and E. C. Kohn
Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling
Clin. Cancer Res., February 1, 2006; 12(3): 791 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Lee, C. B. Fuhrman, V. Planelles, M. R. Peltier, D. K. Gaffney, A. P. Soisson, M. K. Dodson, H. D. Tolley, C. L. Green, and K. A. Zempolich
Phosphatidylinositol 3-Kinase Inhibition by LY294002 Radiosensitizes Human Cervical Cancer Cell Lines
Clin. Cancer Res., January 1, 2006; 12(1): 250 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Parsons
Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer
Clin. Cancer Res., November 15, 2005; 11(22): 7965 - 7966.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Hu, J. Hofmann, and R. B. Jaffe
Phosphatidylinostol 3-Kinase Mediates Angiogenesis and Vascular Permeability Associated with Ovarian Carcinoma
Clin. Cancer Res., November 15, 2005; 11(22): 8208 - 8212.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. D. Westfall and M. K. Skinner
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment
Mol. Cancer Ther., November 1, 2005; 4(11): 1764 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Hu, J. Hofmann, J. Holash, G. D. Yancopoulos, A. K. Sood, and R. B. Jaffe
Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model
Clin. Cancer Res., October 1, 2005; 11(19): 6966 - 6971.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-C. Chen, Y.-N. Su, P.-C. Chou, W.-C. Chiang, M.-C. Chang, L.-S. Wang, S.-C. Teng, and K.-J. Wu
Overexpression of NBS1 Contributes to Transformation through the Activation of Phosphatidylinositol 3-Kinase/Akt
J. Biol. Chem., September 16, 2005; 280(37): 32505 - 32511.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
P. A. Rascoe, X. Cao, J. C. Daniel, S. D. Miller, and W. R. Smythe
Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. C. Coffey, J. H. Wang, M. J. F. Smith, A. Laing, D. Bouchier-Hayes, T. G. Cotter, and H. P. Redmond
Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis: NOVEL ROLE FOR AN OLD ENEMY
J. Biol. Chem., June 3, 2005; 280(22): 20968 - 20977.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways
Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C.-H. Chou, L.-H. Wei, M.-L. Kuo, Y.-J. Huang, K.-P. Lai, C.-A. Chen, and C.-Y. Hsieh
Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer-activating factor
Carcinogenesis, January 1, 2005; 26(1): 45 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. T. Lee Jr., L. S. Steelman, and J. A. McCubrey
Phosphatidylinositol 3'-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells
Cancer Res., November 15, 2004; 64(22): 8397 - 8404.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. D. Skinner, J. Z. Zheng, J. Fang, F. Agani, and B.-H. Jiang
Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1{alpha}, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling
J. Biol. Chem., October 29, 2004; 279(44): 45643 - 45651.
[Abstract] [Full Text] [PDF]

Home page
 Eukaryot CellHome page
J. J. Smith, J. S. Yakisich, G. M. Kapler, E. S. Cole, and D. P. Romero
A {beta}-Tubulin Mutation Selectively Uncouples Nuclear Division and Cytokinesis in Tetrahymena thermophila
Eukaryot. Cell, October 1, 2004; 3(5): 1217 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Castillo, J. Brognard, P. A. Petukhov, C. Zhang, J. Tsurutani, C. A. Granville, M. Li, M. Jung, K. A. West, J. G. Gills, et al.
Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues
Cancer Res., April 15, 2004; 64(8): 2782 - 2792.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. M. Nguyen, G. A. Chen, R. Reddy, W. Tsai, W. D. Schrump, G. Cole Jr, and D. S. Schrump
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway
J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 365 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Sumitomo, T. Asano, J. Asakuma, T. Asano, A. Horiguchi, and M. Hayakawa
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway
Clin. Cancer Res., January 15, 2004; 10(2): 794 - 801.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, J. I. Hofmann, G. D. Yancopoulos, and R. B. Jaffe
Vascular Endothelial Growth Factor-Trap Decreases Tumor Burden, Inhibits Ascites, and Causes Dramatic Vascular Remodeling in an Ovarian Cancer Model
Clin. Cancer Res., November 15, 2003; 9(15): 5721 - 5728.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fraser, B. M. Leung, X. Yan, H. C. Dan, J. Q. Cheng, and B. K. Tsang
p53 Is a Determinant of X-Linked Inhibitor of Apoptosis Protein/Akt-Mediated Chemoresistance in Human Ovarian Cancer Cells
Cancer Res., November 1, 2003; 63(21): 7081 - 7088.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
Blood, September 1, 2003; 102(5): 1824 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al.
Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer
Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shingu, K. Yamada, N. Hara, K. Moritake, H. Osago, M. Terashima, T. Uemura, T. Yamasaki, and M. Tsuchiya
Synergistic Augmentation of Antimicrotubule Agent-induced Cytotoxicity by a Phosphoinositide 3-Kinase Inhibitor in Human Malignant Glioma Cells
Cancer Res., July 15, 2003; 63(14): 4044 - 4047.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, N. Yang, D. Katsaros, W. Huang, J.-W. Park, S. Fracchioli, C. Vezzani, I. A. Rigault de la Longrais, W. Yao, S. C. Rubin, et al.
The Oncogene Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma
Cancer Res., July 15, 2003; 63(14): 4225 - 4231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, M. Rahmani, Y. Dai, D. Conrad, G. Krystal, P. Dent, and S. Grant
The Lethal Effects of Pharmacological Cyclin-dependent Kinase Inhibitors in Human Leukemia Cells Proceed through a Phosphatidylinositol 3-Kinase/Akt-dependent Process
Cancer Res., April 15, 2003; 63(8): 1822 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa
Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel
Cancer Res., March 15, 2003; 63(6): 1365 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Nimbalkar, M. K. Henry, and F. W. Quelle
Cytokine Activation of Phosphoinositide 3-Kinase Sensitizes Hematopoietic Cells to Cisplatin-induced Death
Cancer Res., March 1, 2003; 63(5): 1034 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Jaboin, C. J. Kim, D. R. Kaplan, and C. J. Thiele
Brain-derived Neurotrophic Factor Activation of TrkB Protects Neuroblastoma Cells from Chemotherapy-induced Apoptosis via Phosphatidylinositol 3'-Kinase Pathway
Cancer Res., November 15, 2002; 62(22): 6756 - 6763.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Hu, J. Hofmann, C. Zaloudek, N. Ferrara, T. Hamilton, and R. B. Jaffe
Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer
Am. J. Pathol., November 1, 2002; 161(5): 1917 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. W. Krystal, G. Sulanke, and J. Litz
Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy
Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. Russell
Adenovirus Gene Therapy for Ovarian Cancer
J Natl Cancer Inst, May 15, 2002; 94(10): 706 - 707.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.